Education-only orientation — This page is part of the iMicrodosing.org evidence library. It provides research and regulatory education only. It is not clinical advice, prescribing information, a recommendation to seek or avoid any treatment, or guidance on participating in any clinical program.
What this page does and does not contain — This page examines the clinical and regulatory landscape for psilocybin-based investigational drugs. It names clinical sponsors and trial programs only to identify their public research records and regulatory milestones. It does not: recommend or endorse any treatment, drug, or program; guide readers toward or away from any investigational therapy; facilitate trial enrollment; provide recruitment or site-location information; reproduce or endorse sponsor investor language as established efficacy; apply full-dose clinical trial findings to microdosing; or link to
.comcommerce properties.
Press releases, ClinicalTrials.gov entries, FDA regulatory milestone announcements, and peer-reviewed publications are four different source types that carry different evidentiary weights. Understanding the vocabulary — MADRS scores, p-values, confidence intervals, Breakthrough Therapy designation, CNPV, rolling NDA — is the prerequisite for reading psychedelic clinical trial coverage without overclaiming or underclaiming. This page is a reference framework.
Four source types in the pipeline conversation
Sponsor press releases communicate to investors and the public when a milestone has been reached. They report top-line data selected by the sponsor. They are not peer-reviewed. They establish: “the sponsor reports that X occurred.” Example: Compass Pathways announcing that COMP005 met its primary endpoint. [1] sponsor-press-release Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Link →
ClinicalTrials.gov registry entries are official records of trial design, status, and — once submitted — results. They are not peer-reviewed publications, but they are formal public records that can be checked for exact trial parameters, phase, enrollment status, and completion dates.
FDA regulatory announcements describe process milestones — Breakthrough Therapy designation, CNPV issuance, IND acceptance, NDA filing acceptance. They are official, authoritative about the regulatory process, and categorically different from efficacy determinations. [2] primary-regulatory Commissioner's National Priority Voucher (CNPV) Pilot Program Link →
Peer-reviewed journal publications submit trial methods and results to independent scientific review before publication. They are the highest-evidentiary-weight source for clinical findings, though they too have limitations and can be subject to post-publication analysis.
| Source | Establishes | Does not establish |
|---|---|---|
| Sponsor press release (top-line) | Sponsor-reported primary endpoint result | Peer-reviewed efficacy; approval; generalizability |
| ClinicalTrials.gov | Trial design, phase, status, registry-level results | Peer review; clinical interpretation |
| FDA regulatory milestone announcement | A specific process step occurred | Efficacy; approval; access |
| Peer-reviewed publication | Independently reviewed clinical findings for specific conditions | Efficacy in all populations or all contexts |
Reading the regulatory vocabulary
Breakthrough Therapy designation (BTD): An FDA program that provides enhanced development support for drugs showing early promise for serious conditions. BTD means the FDA sees enough early evidence to warrant closer collaboration — not that efficacy is established or that approval is coming. [3] primary-regulatory Frequently Asked Questions: Breakthrough Therapies Link →
Commissioner’s National Priority Voucher (CNPV): An FDA pilot program that shortens the review window after a complete NDA is filed. The CNPV issued to Compass Pathways in April 2026 means that once the rolling NDA submission is complete, the review could be compressed to one to two months — rather than the standard ten to twelve months. [4] sponsor-press-release Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher Link → It is an accelerator, not a determination.
Rolling NDA: FDA allows the sponsor to submit completed NDA sections before the whole package is ready. This means review begins earlier, but “rolling NDA underway” does not mean the application is complete. Until the NDA is complete and accepted for review, the clock has not fully started.
NDA approval: The outcome of the FDA’s full review. Absent from this list: positive trials, BTD, CNPV, and rolling NDA submission do not individually constitute or guarantee approval.
Reading a MADRS result
The MADRS is scored 0 to 60 for depression severity. In COMP005, Compass Pathways reported a mean MADRS treatment difference of minus 3.6 points at week 6 for COMP360 25 mg versus placebo (p less than 0.001). What this means precisely:
- The active arm showed a 3.6-point greater improvement than placebo, on average, at six weeks
- p less than 0.001 means this difference is unlikely to be a chance finding in this sample
- The 95% confidence interval of minus 5.7 to minus 1.5 means the true effect could be anywhere in that range
- Week 6 is the pre-specified time point; effects at other time points were secondary or exploratory
- MADRS score does not directly translate to individual patient experience or treatment decisions
A minus 3.6-point difference does not mean every participant improved by 3.6 points. Averages reflect distributions. Some participants may have shown larger improvements; others may not have responded.
Red flags in psychedelic trial coverage
These patterns in press releases or news coverage warrant closer scrutiny:
- Using Phase 2 results with Phase 3 language (“the study proved…”)
- Omitting the comparator type (placebo vs. active low-dose)
- Presenting a MADRS or CAPS-5 number without the confidence interval
- Equating a regulatory milestone with approval (“FDA recognized…”)
- Extending TRD findings to general depression or other conditions
- Extending supervised full-dose clinical findings to microdosing
- Treating “highly significant” as equivalent to “large effect size”
See the Legal Status guardrail for coverage of the legal-to-efficacy conflation. See the Clinical Pipeline overview for the current evidence landscape. See the Access cluster for availability-to-safety conflations.
- P-value
- A probability that quantifies how likely the observed result would be if the null hypothesis (no effect) were true. A small p-value means the result is unlikely under the null. It does not quantify effect size or clinical meaningfulness.
- Confidence interval
- A range within which the true treatment effect is estimated to fall with a specified probability (usually 95%). Width reflects precision; location relative to zero determines statistical significance.
- Effect size vs. statistical significance
- A result can be statistically significant but clinically small, or clinically meaningful but not reach significance in a small study. Both concepts matter for evaluating a trial result.
- Pre-specified vs. post-hoc analysis
- Pre-specified analyses were planned before data collection; post-hoc analyses were conducted after seeing the data. Pre-specified primary endpoints carry more weight than post-hoc findings because they are protected from selective reporting.